{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:47:35Z","timestamp":1779925655585,"version":"3.53.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP22K17367"],"award-info":[{"award-number":["JP22K17367"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00280-023-04542-7","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T07:02:08Z","timestamp":1684479728000},"page":"7-14","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Fluoropyrimidine usage in cases with hyperammonemia: real-world data study using the Japanese Adverse Drug Event Report (JADER) database"],"prefix":"10.1007","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4907-4647","authenticated-orcid":false,"given":"Mitsuaki","family":"Oura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4739-7589","authenticated-orcid":false,"given":"Fumiya","family":"Oguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4605-5985","authenticated-orcid":false,"given":"Nobukazu","family":"Agatsuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Imamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3313-1990","authenticated-orcid":false,"given":"Yoshitaka","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,19]]},"reference":[{"key":"4542_CR1","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3:330\u2013338. https:\/\/doi.org\/10.1038\/nrc1074","journal-title":"Nat Rev Cancer"},{"key":"4542_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2019.09.028","volume":"124","author":"C Barin-Le Guellec","year":"2020","unstructured":"Barin-Le Guellec C, Lafay-Chebassier C, Ingrand I et al (2020) Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: a real-life evaluation in France. Eur J Cancer 124:37\u201346. https:\/\/doi.org\/10.1016\/j.ejca.2019.09.028","journal-title":"Eur J Cancer"},{"key":"4542_CR3","doi-asserted-by":"publisher","first-page":"107447","DOI":"10.1016\/j.pharmthera.2019.107447","volume":"206","author":"S Vodenkova","year":"2020","unstructured":"Vodenkova S, Buchler T, Cervena K et al (2020) 5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future. Pharmacol Ther 206:107447. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107447","journal-title":"Pharmacol Ther"},{"key":"4542_CR4","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1111\/cts.12981","volume":"14","author":"TJ Wigle","year":"2021","unstructured":"Wigle TJ, Povitz BL, Medwid S et al (2021) Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events. Clin Transl Sci 14:1338\u20131348. https:\/\/doi.org\/10.1111\/cts.12981","journal-title":"Clin Transl Sci"},{"key":"4542_CR5","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1200\/JCO.20.02232","volume":"39","author":"JR Hecht","year":"2021","unstructured":"Hecht JR, Lonardi S, Bendell J et al (2021) Randomized Phase III study of FOLFOX alone or with Pegilodecakin as second-line therapy in patients with metastatic pancreatic cancer that progressed after gemcitabine (Sequoia). J Clin Oncol 39:1108\u20131118. https:\/\/doi.org\/10.1200\/JCO.20.02232","journal-title":"J Clin Oncol"},{"key":"4542_CR6","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","volume":"18","author":"HS Wasan","year":"2017","unstructured":"Wasan HS, Gibbs P, Sharma NK et al (2017) First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol 18:1159\u20131171. https:\/\/doi.org\/10.1016\/S1470-2045(17)30457-6","journal-title":"Lancet Oncol"},{"key":"4542_CR7","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1200\/JCO.2018.78.3183","volume":"36","author":"S Qin","year":"2018","unstructured":"Qin S, Li J, Wang L et al (2018) Efficacy and tolerability of first-line cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX-4) versus FOLFOX-4 in patients with RAS wild-type metastatic colorectal cancer: the open-label, randomized, phase III TAILOR trial. J Clin Oncol 36:3031\u20133039. https:\/\/doi.org\/10.1200\/JCO.2018.78.3183","journal-title":"J Clin Oncol"},{"key":"4542_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G et al (2016) Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet 387:545\u2013557. https:\/\/doi.org\/10.1016\/S0140-6736(15)00986-1","journal-title":"Lancet"},{"key":"4542_CR9","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.1992.10.11.1795","volume":"10","author":"M de Forni","year":"1992","unstructured":"de Forni M, Malet-Martino MC, Jaillais P et al (1992) Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 10:1795\u20131801. https:\/\/doi.org\/10.1200\/JCO.1992.10.11.1795","journal-title":"J Clin Oncol"},{"key":"4542_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","volume":"134","author":"C Kosmas","year":"2008","unstructured":"Kosmas C, Kallistratos MS, Kopterides P et al (2008) Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 134:75\u201382. https:\/\/doi.org\/10.1007\/s00432-007-0250-9","journal-title":"J Cancer Res Clin Oncol"},{"key":"4542_CR11","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/annonc\/mdf089","volume":"13","author":"J Cassidy","year":"2002","unstructured":"Cassidy J, Twelves C, Van Cutsem E et al (2002) First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil\/leucovorin. Ann Oncol 13:566\u2013575. https:\/\/doi.org\/10.1093\/annonc\/mdf089","journal-title":"Ann Oncol"},{"key":"4542_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1517\/14740338.2011.546342","volume":"10","author":"MW Saif","year":"2011","unstructured":"Saif MW (2011) Capecitabine and hand\u2013foot syndrome. Expert Opin Drug Saf 10:159\u2013169. https:\/\/doi.org\/10.1517\/14740338.2011.546342","journal-title":"Expert Opin Drug Saf"},{"key":"4542_CR13","doi-asserted-by":"publisher","unstructured":"Mitani S, Kadowaki S, Komori A et al (2017) Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy. Medicine 96:1\u20135. https:\/\/doi.org\/10.1097\/MD.0000000000006874","DOI":"10.1097\/MD.0000000000006874"},{"key":"4542_CR14","doi-asserted-by":"publisher","first-page":"4216752","DOI":"10.1155\/2020\/4216752","volume":"2020","author":"M Chahin","year":"2020","unstructured":"Chahin M, Krishnan N, Chhatrala H, Shaikh M (2020) A 5-fluorouracil-induced hyperammonemic encephalopathy challenged with capecitabine. Case Rep Oncol Med 2020:4216752. https:\/\/doi.org\/10.1155\/2020\/4216752","journal-title":"Case Rep Oncol Med"},{"key":"4542_CR15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejca.2020.01.019","volume":"129","author":"A Boil\u00e8ve","year":"2020","unstructured":"Boil\u00e8ve A, Thomas L, Lillo-Le Lou\u00ebt A et al (2020) 5-fluorouracil-induced hyperammonaemic encephalopathy: a French national survey. Eur J Cancer 129:32\u201340. https:\/\/doi.org\/10.1016\/j.ejca.2020.01.019","journal-title":"Eur J Cancer"},{"key":"4542_CR16","first-page":"193","volume":"51","author":"H Yamamoto","year":"2015","unstructured":"Yamamoto H, Takeshige Y, Miyakawa T, Sagara Y (2015) Risk of hyperammonemia in patients with chemotherapy (mFOLFOX6). J Jpn Soc Hosp Pharm 51:193\u2013196 (article in Japanese)","journal-title":"J Jpn Soc Hosp Pharm"},{"key":"4542_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00280-017-3249-1","volume":"79","author":"Y Nishikawa","year":"2017","unstructured":"Nishikawa Y, Funakoshi T, Horimatsu T et al (2017) Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. Cancer Chemother Pharmacol 79:629\u2013633. https:\/\/doi.org\/10.1007\/s00280-017-3249-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"4542_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.21873\/invivo.11511","volume":"33","author":"Y Hara","year":"2019","unstructured":"Hara Y, Miyamoto Y, Hiyoshi Y et al (2019) Severe encephalopathy, lactic acidosis and hyperammonaemia with FOLFIRI plus aflibercept after two-stage hepatectomy: a case report. In Vivo 33:563\u2013565. https:\/\/doi.org\/10.21873\/invivo.11511","journal-title":"In Vivo"},{"key":"4542_CR19","first-page":"1632","volume":"46","author":"S Sawazaki","year":"2019","unstructured":"Sawazaki S, Numata M, Ju M et al (2019) A case altered consciousness due to 5-fluorouracil-induced hyperammonemia in a patient with recurrent colorectal cancer. Gan To Kagaku Ryoho 46:1632\u20131634 (article in Japanese)","journal-title":"Gan To Kagaku Ryoho"},{"key":"4542_CR20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.11405\/nisshoshi.112.287","volume":"112","author":"T Iida","year":"2015","unstructured":"Iida T, Wagatsuma K, Tani M et al (2015) Four cases of 5-fluorouracil-related hyperammonemia in patients with large intestinal cancer and multiple liver metastases, including a case of hyperammonemia treated using hemodialysis. Nihon Shokakibyo Gakkai Zasshi 112:287\u2013296. https:\/\/doi.org\/10.11405\/nisshoshi.112.287. (article in Japanese)","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"4542_CR21","doi-asserted-by":"publisher","first-page":"933","DOI":"10.4030\/jjcs.40.933","volume":"40","author":"Y Yamamura","year":"2015","unstructured":"Yamamura Y, Umemoto K, Suzuki T et al (2015) A case of disturbance of consciousness due to hyperammonemia induced by 5-FU in a patient with recurrent rectal cancer. JJCS 40:933\u2013937. https:\/\/doi.org\/10.4030\/jjcs.40.933. (article in Japanese)","journal-title":"JJCS"},{"key":"4542_CR22","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s00280-020-04158-1","volume":"86","author":"Y Ozaki","year":"2020","unstructured":"Ozaki Y, Imamaki H, Ikeda A et al (2020) Successful management of hyperammonemia with hemodialysis on day 2 during 5-fluorouracil treatment in a patient with gastric cancer: a case report with 5-fluorouracil metabolite analyses. Cancer Chemother Pharmacol 86:693\u2013699. https:\/\/doi.org\/10.1007\/s00280-020-04158-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"4542_CR23","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/00001813-199903000-00004","volume":"10","author":"CC Liaw","year":"1999","unstructured":"Liaw CC, Wang HM, Wang CH et al (1999) Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection. Anticancer Drugs 10:275\u2013281. https:\/\/doi.org\/10.1097\/00001813-199903000-00004","journal-title":"Anticancer Drugs"},{"key":"4542_CR24","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1159\/000510258","volume":"43","author":"B W\u00f6rmann","year":"2020","unstructured":"W\u00f6rmann B, Bokemeyer C, Burmeister T et al (2020) Dihydropyrimidine dehydrogenase testing prior to treatment with 5-fluorouracil, capecitabine, and tegafur: a consensus paper. Oncol Res Treat 43:628\u2013636. https:\/\/doi.org\/10.1159\/000510258","journal-title":"Oncol Res Treat"},{"key":"4542_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.anl.2007.04.012","volume":"35","author":"S Kikuta","year":"2008","unstructured":"Kikuta S, Asakage T, Nakao K, Sugasawa M, Kubota A (2008) The aggravating factors of hyperammonemia related to 5-fluorouracil infusion-A report of two cases. Auris Nasus Larynx 35:295\u2013299. https:\/\/doi.org\/10.1016\/j.anl.2007.04.012","journal-title":"Auris Nasus Larynx"},{"key":"4542_CR26","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-08-2242","volume":"15","author":"CMM Prado","year":"2009","unstructured":"Prado CMM, Baracos VE, McCargar LJ et al (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15:2920\u20132926. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2242","journal-title":"Clin Cancer Res"},{"key":"4542_CR27","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1159\/000502512","volume":"12","author":"C Funasaka","year":"2019","unstructured":"Funasaka C, Kanemasa Y, Shimoyama T, Ohta A, Omuro Y (2019) Modified FOLFOX-6 plus bevacizumab chemotherapy for metastatic colorectal cancer in patients receiving hemodialysis: a report of three cases and review of the literature. Case Rep Oncol 12:657\u2013665. https:\/\/doi.org\/10.1159\/000502512","journal-title":"Case Rep Oncol"},{"key":"4542_CR28","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s10147-021-01932-w","volume":"26","author":"K Okamoto","year":"2021","unstructured":"Okamoto K, Nozawa H, Hongo K et al (2021) Risk factors of mFOLFOX6-induced hyperammonemia in patients with colorectal cancer: an observational study. Int J Clin Oncol 26:1477\u20131484. https:\/\/doi.org\/10.1007\/s10147-021-01932-w","journal-title":"Int J Clin Oncol"},{"key":"4542_CR29","unstructured":"Ministry of Justice (2015) Act on securing quality, efficacy and safety of products including pharmaceuticals and medical devices. In: Japanese Law Transl. Database Syst. https:\/\/www.japaneselawtranslation.go.jp\/ja\/laws\/view\/3213. Accessed 23 Sep 2022"},{"key":"4542_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"SV van Buuren","year":"2011","unstructured":"van Buuren SV, Groothuis-Oudshoorn K (2011) Mice: multivariate imputation by chained equations in R. J Stat Soft 45:1\u201367. https:\/\/doi.org\/10.18637\/jss.v045.i03","journal-title":"J Stat Soft"},{"key":"4542_CR31","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1093\/bioinformatics\/btr406","volume":"27","author":"U Bodenhofer","year":"2011","unstructured":"Bodenhofer U, Kothmeier A, Hochreiter S (2011) APCluster: an R package for affinity propagation clustering. Bioinformatics 27:2463\u20132464. https:\/\/doi.org\/10.1093\/bioinformatics\/btr406","journal-title":"Bioinformatics"},{"key":"4542_CR32","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1126\/science.1136800","volume":"315","author":"BJ Frey","year":"2007","unstructured":"Frey BJ, Dueck D (2007) Clustering by passing messages between data points. Science 315:972\u2013976. https:\/\/doi.org\/10.1126\/science.1136800","journal-title":"Science"},{"key":"4542_CR33","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s40261-017-0503-6","volume":"37","author":"C Michel","year":"2017","unstructured":"Michel C, Scosyrev E, Petrin M, Schmouder R (2017) Can disproportionality analysis of post-marketing case reports be used for comparison of drug safety profiles? Clin Drug Investig 37:415\u2013422. https:\/\/doi.org\/10.1007\/s40261-017-0503-6","journal-title":"Clin Drug Investig"},{"key":"4542_CR34","first-page":"483","volume":"40","author":"N Misumi","year":"2013","unstructured":"Misumi N, Goto T, Miyoshi T et al (2013) Risk factors for hyperammonemia during mFOLFOX6 treatment. Gan To Kagaku Ryoho 40:483\u2013487 (article in Japanese)","journal-title":"Gan To Kagaku Ryoho"},{"key":"4542_CR35","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/bjc.1997.79","volume":"75","author":"KH Yeh","year":"1997","unstructured":"Yeh KH, Cheng AL (1997) High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy. Br J Cancer 75:464\u2013465","journal-title":"Br J Cancer"},{"key":"4542_CR36","first-page":"335","volume":"31","author":"PP Advani","year":"2011","unstructured":"Advani PP, Fakih MG (2011) 5-FU-induced hyperammonemic encephalopathy in a case of metastatic rectal adenocarcinoid successfully rechallenged with the fluoropyrimidine analog, capecitabine. Anticancer Res 31:335\u2013338","journal-title":"Anticancer Res"},{"key":"4542_CR37","doi-asserted-by":"publisher","first-page":"896","DOI":"10.3919\/jjsa.77.896","volume":"77","author":"K Kihara","year":"2016","unstructured":"Kihara K, Kono Y, Suzuki K et al (2016) Modified FOLFOX6 induced hyperammonemic encephalopathy in a case of metastatic sigmoid colon cancer successfully rechallenged with CapeOX. J Jpn Surg Assoc 77:896\u2013903. https:\/\/doi.org\/10.3919\/jjsa.77.896. (article in Japanese)","journal-title":"J Jpn Surg Assoc"},{"key":"4542_CR38","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2165\/00003088-200140020-00002","volume":"40","author":"B Reigner","year":"2001","unstructured":"Reigner B, Blesch K, Weidekamm E (2001) Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 40:85\u2013104. https:\/\/doi.org\/10.2165\/00003088-200140020-00002","journal-title":"Clin Pharmacokinet"},{"key":"4542_CR39","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/BF00686286","volume":"35","author":"L Thiberville","year":"1994","unstructured":"Thiberville L, Compagnon P, Moore N et al (1994) Plasma 5-fluorouracil and alpha-fluoro-beta-alanin accumulation in lung cancer patients treated with continuous infusion of cisplatin and 5-fluorouracil. Cancer Chemother Pharmacol 35:64\u201370. https:\/\/doi.org\/10.1007\/BF00686286","journal-title":"Cancer Chemother Pharmacol"},{"key":"4542_CR40","doi-asserted-by":"publisher","first-page":"102218","DOI":"10.1016\/j.ctrv.2021.102218","volume":"98","author":"B Glimelius","year":"2021","unstructured":"Glimelius B, Stintzing S, Marshall J, Yoshino T, de Gramont A (2021) Metastatic colorectal cancer: advances in the folate-fluoropyrimidine chemotherapy backbone. Cancer Treat Rev 98:102218. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102218","journal-title":"Cancer Treat Rev"},{"key":"4542_CR41","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1056\/NEJMra1515442","volume":"374","author":"RM Navari","year":"2016","unstructured":"Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374:1356\u20131367. https:\/\/doi.org\/10.1056\/NEJMra1515442","journal-title":"N Engl J Med"},{"key":"4542_CR42","first-page":"2203","volume":"47","author":"GD Heggie","year":"1987","unstructured":"Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203\u20132206","journal-title":"Cancer Res"},{"key":"4542_CR43","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1001\/archneur.1970.00480260061008","volume":"23","author":"H Koenig","year":"1970","unstructured":"Koenig H, Patel A (1970) Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate. Arch Neurol 23:155\u2013160. https:\/\/doi.org\/10.1001\/archneur.1970.00480260061008","journal-title":"Arch Neurol"},{"key":"4542_CR44","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00467-011-1838-5","volume":"27","author":"A Auron","year":"2012","unstructured":"Auron A, Brophy PD (2012) Hyperammonemia in review: pathophysiology, diagnosis, and treatment. Pediatr Nephrol 27:207\u2013222. https:\/\/doi.org\/10.1007\/s00467-011-1838-5","journal-title":"Pediatr Nephrol"},{"key":"4542_CR45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13613-022-01026-4","volume":"12","author":"A Balcerac","year":"2022","unstructured":"Balcerac A, Bihan K, Lebrun-Vignes B et al (2022) Drug-associated hyperammonaemia: a Bayesian analysis of the WHO pharmacovigilance database. Ann Intensive Care 12:55. https:\/\/doi.org\/10.1186\/s13613-022-01026-4","journal-title":"Ann Intensive Care"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04542-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-023-04542-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-023-04542-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T11:04:46Z","timestamp":1686567886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-023-04542-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["4542"],"URL":"https:\/\/doi.org\/10.1007\/s00280-023-04542-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,19]]},"assertion":[{"value":"23 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HI received lecture fees outside the submitted work from Kyowa Kirin Company, Limited, Kowa Co., Ltd, AstraZeneca K.K., Taisho Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Novo Nordisk A\/S, Sumitomo Pharma Co., Ltd. All other authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was entirely based on an anonymized open database, and thus, ethical approval was not required. This study was conducted in accordance with the terms of use of the Japanese Adverse Drug Event Report database provided by Pharmaceuticals and Medical Devices Agency.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study was based on an anonymized database that can be widely downloaded by anyone, and consent to participate was not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}